



# SANTA MARTA

Life Sciences

## COMPANY HIGHLIGHTS

*Santa Marta Life Sciences ("SMLS") is a Canadian company with Colombian based operations, specializing in cultivation, processing and manufacturing of medical-grade, bulk cannabinoid extracts for the global marketplace. With its production facility strategically located in the foothills of the Sierra Nevada de Santa Marta mountains, SMLS benefits from a tropical, equatorial climate and dry winds, creating the ideal natural location for cannabis growth. The company's key differentiators (as listed below) allow it to supply manufacturers with cost-effective, stable cannabinoid inputs, while strictly managing competitive production and extraction costs, high profits and a low cash burn.*

- Unparalleled Expertise Means Immediate Results.** The management, cultivation & extraction team have a combined 85 years of commercial-scale industry experience and expertise. The team feature's the managing director of Canalis Capital, founding CEO/Chairman of Pharmacielo (PCLO.V) & Blueberries Medical Corp.(BBM.CN), former management from Mircale Valley, former advisors to Tokyo Smoke, Khiron (KHRN.V), & co-founder of All Nation Cannabis.
- Soaring Global Demand.** Global demand for medical cannabis is expected to increase 48x by the year 2027. Colombia is poised to capture a significant portion of this demand, with the United Nations' International Narcotics Control Board estimating it will account for 21.84% of global production.
- Fully Licensed.** SMLS has all four cannabis licenses from the Colombian government, including: (1) Cultivation of Non-Psychoactive Cannabis; (2) Cultivation of Psychoactive Cannabis; (3) Manufacture & Export of Cannabis Derivatives (Extraction & Processing); and (4) Distribution of Seeds/Genetics.
- Proven Agricultural Land.** 25-year lease on 34.5 hectares in the agricultural region of Santa Marta, including a 10,000 ft<sup>2</sup> greenhouse, laboratory and R&D lab already constructed on the property. Located in the foothills of the Sierra Nevada de Santa Marta mountains, the production facility enjoys the same tropical climate and dry winds that have made this region of Colombia an agricultural hub for the Americas.
- Unique Extraction Technology and Processes.** SMLS will use the latest ethanol extraction equipment and processes from world-renowned Canadian company, Evolved Extraction. The EV-MASS ethanol extraction solution will be the 'first of its kind' in Colombia and features some of the most efficient extraction technology available on the market, including a solvent recovery system and customizable modular construction.
- Secured Near-Term Revenue Streams.** Agreements for the export of bulk cannabinoid extracts through an established distribution network. The company has secured distribution agreements for medical-grade cannabis extracts in the UK, EU, USA, Canada, Mexico, and Colombia, as legally permitted, including an MOU for 2000L of CBD winterized crude oil, and 300L of CBG winterized crude oil.
- Capital Structure.** 19.8M s/o, 2.4M options and warrants, 70% held by founders and insiders.
- Near term Liquidity Event.** SMLS is expecting a TSXV or CSE listing by mid-late 2021.
- Capital Raise.** SMLS is raising a minimum of \$3M at a \$7M pre-money valuation. This will allow the Company to reach important revenue milestones and become cash flow positive.
- Attractive Entry Point.** SMLS offers substantial potential upside to investors at its current valuation, especially as compared to its Colombian peers (see chart below).

Company	Market Cap (Feb. 2021)
Avicanna (TSX)	\$49m CAD
Khiron (TSXV)	\$79m CAD
Pharmacielo (TSXV)	\$334m CAD
Clever Leaves (NASDAQ)	\$390m USD
Blueberries Medical Corp. (CSE)	\$24m CAD
Santa Marta Life Sciences**	\$7m CAD

\*\* RTO planned on CDN exchange in 2021

**The Future of Cannabis Starts in Colombia.**




# SANTA MARTA

Life Sciences

## SMLS 5-year Proforma

	2021	2022	2023	2024	2025
Revenues	\$-	\$ 8,765,625	\$ 24,248,798	\$ 51,497,596	\$ 100,456,731
Expenses	\$-	\$ 3,498,344	\$ 12,898,197	\$ 24,724,904	\$ 47,206,010
EBITDA	\$ (898,546)	\$ 2,718,609	\$ 4,304,042	\$ 14,418,097	\$ 34,392,216
	\$-	\$	\$	\$	\$
CAPEX	\$ (2,770,000)	\$ (1,467,856)	\$ (4,000,000)		

## SMLS Proforma Revenue (Blue) and EBITDA (Green) (CAD).



## WHY COLOMBIA?

According to Stephen Murphy, Managing Director of research firm Prohibition Partners, "With the legalization of Canada's recreational cannabis market, all eyes have been on North America, but actually it's the Latin American region that has quietly been carving out industry firsts. Colombia has become one of the world's most attractive cannabis markets as international cannabis companies take advantage of favourable export laws. We believe that the expansion of a Latin American market will significantly impact the global cannabis industry, undercutting producers and pricing worldwide. Strong forecast population growth, a perfect climate for cannabis cultivation, bolstered by progressive legislation and regulatory change are set to ensure Latin America, particularly Colombia, remains a very attractive prospect for cannabis companies, and investors."

The Future of Cannabis Starts in Colombia.



SANTA MARTA

Life Sciences



The Future of Cannabis Starts in Colombia.